Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript Biotech advances RAS-inhibitor pipeline with $3.9B cash and FDA acceptance of daraxonrasib NDA.
Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years Revolution Medicines (
NASDAQ:RVMD ) has outperformed the market over the past 5 years by 38.08% on an annualized basis producing an average annual return of 49.88%. Currently, Revolution Medicines has a market
Revolution Medicines Q2 Earnings Call Highlights Revolution Medicines (
NASDAQ:RVMD ) said its second-quarter 2026 results reflected continued investment in late-stage cancer programs, commercial launch preparations and manufacturing capacity as it advances daraxonrasib and other RAS-targeted therapies across pancreatic and lung cancer.
The company
Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock The company is on the verge of becoming a commercial-stage biotech, with two promising therapies in phase 3 trials.
Better Growth Buy: Axsome vs Revolution Medicines These stocks both scored a win in the first half of the year.
Can Revolution Medicines Be a Game-Changer Stock? This company's potential pancreatic cancer blockbuster could be a watershed moment.
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates.
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
This Nuclear Tech Stock Grew Revenue 27%, But a Fund Still Slashed Its Stake Mirion Technologies delivers radiation detection and monitoring solutions to healthcare and industrial clients worldwide.
This Retail Stock Is Down 10% in a Year Despite Record Revenue. A Fund Just Cut Its Stake This global retailer offers apparel and accessories across multiple brands and channels in North America, Europe, and Asia.
This Trade School Stock Is Up 135%. Here’s Why a Fund Still Bought 459,000 Shares Lincoln Educational Services delivers hands-on technical and healthcare training across 22 campuses, serving workforce needs nationwide.
Callaway Stock Has Soared 150%. Here’s Why One Fund Still Bought 1.1 Million Shares Callaway Golf Company combines branded equipment sales with experiential entertainment through its Topgolf venues and lifestyle offerings.
